QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia
CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
CHICAGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company…
